Appeal No. 2005-0545
Application No. 09/989,019
col. 2, l. 55-63) to promote lean body mass while simultaneously
reducing body fat (Majeed, col. 1, l. 67, to col. 2, l. 6, and
col. 3, l. 37-53). Majeed states, “It is well known in the
literature that forskohlin is related to lipolysis in isolated fat
cells . . .” (Majeed, col. 2, l. 19-35). Suitable carriers,
diluents and excipients for topical administration of forskohli are
said to be well known in the art (Majeed, col. 4, l. 47-49).
Kuppusamy teaches that the flavonoids “quercetin and fisetin
were potent PDE [phosphodiesterase] inhibitors which were also among
the more active lipolytic compounds (Table 2). Fisetin was only
half as potent, as a PDE inhibitor, when compared to quercetin but
showed greater lipolytic activity than quercetin” (Kuppusamy,
p. 1312, col. 2). See Kuppusamy’s Table 2 (p. 1309) for the
comparative PDE activity and lipolysis of other test compounds
including theophylline, genistein, and daidzein. Moreover, fisetin
and quercetin caused a synergistic increase in lipolysis in the
presence of other drugs (Kuppusamy, p. 1313, col. 2, to p. 1314,
col. 1). The prior art recognized that “[c]ompounds that cause
direct lipolysis may have a use in anti-obesity therapy . . .”
(Kuppusamy, p. 1307, col. 2).
Lotte (English translation of Japanese Patent Publication Hei
7-61927) teaches one or more (Lotte, p. 9) lipase-inhibiting agents
10
Page: Previous 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Last modified: November 3, 2007